Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07050732 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
A Phase 2 study of Respiratory Syncytial Virus (RSV), sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT07050732: Recruiting Phase 2 study of Respiratory Syncytial Virus (RSV), sponsored by Johns Hopkins University.
NCT07050732 is a Phase 2 study of Respiratory Syncytial Virus (RSV) that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 170 participants, below the 6,741-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07050732, a Phase 2 study of Respiratory Syncytial Virus (RSV), is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune systems? * What medical problems do participants have after receiving Arexvy? Participants with weakened immune systems will: * Receive 3 study vaccines over the course of 1 year * Keep a diary of symptoms for 7 days after each vaccine * Have 3 in-person follow up study visits for checkups and tests over the course of 1.5 years * Have 6 phone follow up study visits over the course of 1.5 years
Primary Outcome
Immune response elicited by adjuvanted RSVPreF3 (Arexvy) in immunocompromised adults as determined by titers of neutralizing antibody estimated dilution 60 (ED60) against RSV A and B
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Arexvy (2 doses total)
- BIOLOGICAL Arexvy (3 doses total)
- BIOLOGICAL Arexvy (1 dose total)
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What NCT07050732 shows while recruiting
NCT07050732 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 6,741-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07050732 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07050732 about?
NCT07050732 is a clinical study titled "Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons". This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune sys...
What is the current status of trial NCT07050732?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2025-12-04. Estimated completion is 2028-04.
What conditions does trial NCT07050732 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV).
What interventions are being tested in trial NCT07050732?
The interventions under investigation include: Placebo (OTHER), Arexvy (2 doses total) (BIOLOGICAL), Arexvy (3 doses total) (BIOLOGICAL), Arexvy (1 dose total) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07050732?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07050732 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus (RSV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07050732's enrollment target sits among peer trials
170 8th of 11 higher than 4 of 11 other Respiratory Syncytial Virus (RSV) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus (RSV) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate EDP 938 Regimens in Children With RSV
COMPLETED · Phase 2
-
RSV Vaccine Pregnancy Registry
RECRUITING
-
Systems Biological Analysis of Immune Responses to RSV Vaccine
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
ACTIVE NOT RECRUITING · Phase 1
-
Transplacental Transmission of RSV (TTRSV)
ACTIVE NOT RECRUITING
-
Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI